Roy Elias

6PUBLICATIONS
43CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 17, 2026
Integrated Pathologic, Genomic, and Transcriptomic Analysis of Renal Neuroendocrine Tumors Reveals Neuroendocrine Transcriptional Programs and Associated Gastrointestinal-Type Epithelium in a Subset of Cases.

|Mar 25, 2025
Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity.

Roy Elias, Thomas Nirschl, Michael Rezaee

|Sep 08, 2022
ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.

Aditi Mulgaonkar, Roy Elias, Layton Woolford

|Jul 02, 2021
Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.

Durga Udayakumar, Ze Zhang, Yin Xi

|Nov 07, 2020
Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.

Britney Reese, Ashok Silwal, Elizabeth Daugherity

|Nov 03, 2020
Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.

Viral Patel, Roy Elias, Joseph Formella

Pageof 1

Frequent Collaborators

2 joint publications

James Brugarolas

2 joint publications

Yasser Ged

2 joint publications

Ezra Baraban

2 joint publications

Nirmish Singla